Hepa Thera
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Hepa Thera - overview
Established
2021
Location
Shanghai, Shanghai, China
Primary Industry
Pharmaceuticals
About
Based in Suzhou, China, and founded in 2021, Suzhou HepaThera Biotech Co. , Ltd. provides therapeutic treatments for the biopharmaceutical sector. The CEO of the company, Yanqin Ma, was the vice president of Jiangsu Enhua Pharmaceutical Research Institute, and the CMO, Shanzhong Zhang, worked at Shanghai First People's Hospital.
In May 2026, the firm raised over CNY 630 million in series B funding. The company works with research institutions and medical networks to provide liver disease treatments through a combination of proprietary research and licensed assets. Its core pipeline includes the HT-101 small interfering RNA injection and the HT-102 neutralizing antibody, which are utilized as a combination therapy to treat chronic hepatitis B. The company generates revenue from business-to-business contracts through the licensing, collaborative development, and commercialization of its therapeutic drug pipelines and pipeline assets.
The company plans to use the Series B funding to advance the global clinical development and registration filing of its core products, expand combination therapy strategies, build commercialization and industrialization capabilities, and strengthen capital market planning.
Current Investors
Fosun Health Capital, Tahoe VC, Nanjing Zhongyiren Investment
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.hepathera.com/
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Hepa Thera - financials
| Fiscal Year Ended | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|
| Revenue (USD) | - | - |
| % Revenue Growth (YoY) | - | - |
| EBITDA (USD) | - | - |
| Operating Income (USD) | - | - |
| Operating Margin | - | - |
| % EBITDA Margin | - | - |
| NET Income (USD) | - | - |
| % Net Margin | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.